Earlier Abiraterone Use May Benefit Prostate Cancer Patients

I don't know if these articles have been posted yet, but it's always a good sign when a clinical trial's ended early due to good results. It will still take several months for approval after the company submits their request for approval, which should be sometime this year.

http://www.nytimes.com/2012/03/09/business/trial-shows-benefit-in-earlier-use-of-zytiga-for-prostate-cancer.html?_r=1

http://www.bloomberg.com/news/2012-03-08/johnson-johnson-zytiga-study-sets-up-challenge-to-dendreon-s-provenge.html

 

Looks encouraging, except for the cost. Perhaps if the label use becomes more universal, J & J will lower the price so that it could better compete with Lupron, etc.

BTW: I am not a new member; just haven't been on here for awhile (Joey G) and forgot my sign-on info.